These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 21393611

  • 1. Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy.
    Cruzado JM, Poveda R, Ibernón M, Díaz M, Fulladosa X, Carrera M, Torras J, Bestard O, Navarro I, Ballarín J, Romero R, Grinyó JM.
    Nephrol Dial Transplant; 2011 Nov; 26(11):3596-602. PubMed ID: 21393611
    [Abstract] [Full Text] [Related]

  • 2. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
    Luna E, Cerezo I, Macias R, Villa J, Martinez C, Cubero J, Martinez R, Ferreira F, García C.
    Transplant Proc; 2011 Nov; 43(6):2187-90. PubMed ID: 21839229
    [Abstract] [Full Text] [Related]

  • 3. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran.
    Soleymanian T, Najafi I, Salimi BH, Broomand B.
    Ren Fail; 2011 Nov; 33(6):572-7. PubMed ID: 21663387
    [Abstract] [Full Text] [Related]

  • 4. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 5. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 6. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 27; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 7. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C, Torres DD, Rossini M, Pesce F, Schena FP.
    Nephrol Dial Transplant; 2009 Dec 27; 24(12):3694-701. PubMed ID: 19628647
    [Abstract] [Full Text] [Related]

  • 8. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.
    Transplantation; 2007 Aug 27; 84(4):467-74. PubMed ID: 17713429
    [Abstract] [Full Text] [Related]

  • 9. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, Holdaas H, Krcmery S, Kobalava Z, Amlodipine Versus Enalapril in Renal failure (AVER) Study Group.
    Clin Ther; 2008 Mar 27; 30(3):482-98. PubMed ID: 18405787
    [Abstract] [Full Text] [Related]

  • 10. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.
    Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM.
    Am J Kidney Dis; 2001 Jul 27; 38(1):18-25. PubMed ID: 11431176
    [Abstract] [Full Text] [Related]

  • 11. Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor.
    Li PK, Kwan BC, Chow KM, Leung CB, Szeto CC.
    Am J Med; 2013 Feb 27; 126(2):162-8. PubMed ID: 23331443
    [Abstract] [Full Text] [Related]

  • 12. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
    Trimarchi H, Muryan A, Young P, Forrester M, Iotti A, Pereyra H, Lombi F, Seminario O, Alonso M, Iotti R.
    Medicina (B Aires); 2007 Feb 27; 67(5):445-50. PubMed ID: 18051227
    [Abstract] [Full Text] [Related]

  • 13. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.
    Bianchi S, Bigazzi R, Campese VM.
    Am J Kidney Dis; 2010 Apr 27; 55(4):671-81. PubMed ID: 20097461
    [Abstract] [Full Text] [Related]

  • 14. Factors associated with proteinuria in renal transplant recipients treated with sirolimus.
    Liew A, Chiang GS, Vathsala A.
    Transpl Int; 2009 Mar 27; 22(3):313-22. PubMed ID: 19054382
    [Abstract] [Full Text] [Related]

  • 15. Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study.
    Pankewycz O, Leca N, Kohli R, Weber-Shrikant E, Said M, Alnimri M, Feng L, Patel S, Laftavi MR.
    Transplant Proc; 2011 Mar 27; 43(2):519-23. PubMed ID: 21440749
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.
    Aliabadi AZ, Mahr S, Dunkler D, Grömmer M, Zimpfer D, Wolner E, Grimm M, Zuckermann AO.
    Transplantation; 2008 Dec 27; 86(12):1771-6. PubMed ID: 19104420
    [Abstract] [Full Text] [Related]

  • 17. Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification).
    Edström Halling S, Söderberg MP, Berg UB.
    Nephrol Dial Transplant; 2012 Feb 27; 27(2):715-22. PubMed ID: 21750154
    [Abstract] [Full Text] [Related]

  • 18. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
    Morales JM, Hartmann A, Walker R, Arns W, Senatorski G, Grinyó JM, Shoker A, Wilczek H, Jamieson NV, Lelong M, Brault Y, Burke JT, Scarola JA, Rapamune Maintenance Regimen Study Group.
    Transplant Proc; 2009 Feb 27; 41(6):2339-44. PubMed ID: 19715914
    [Abstract] [Full Text] [Related]

  • 19. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol.
    Eitner F, Ackermann D, Hilgers RD, Floege J.
    J Nephrol; 2008 Feb 27; 21(3):284-9. PubMed ID: 18587715
    [Abstract] [Full Text] [Related]

  • 20. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
    Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, Wang H.
    Am J Kidney Dis; 2009 Jan 27; 53(1):26-32. PubMed ID: 18930568
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.